Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
explore the efficacy and safety of the combination of nintedanib and paclitaxel in the
neoadjuvant treatment of HER2 positive early or locally advanced breast cancer